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Host defenses against Streptococcus pneumoniae depend largely on opsonophagocytosis mediated by antibod-
ies and complement. Since pneumococcus is a respiratory pathogen, mucosal immune responses may play a
significant role in the defense against pneumococcal infections. Thus, mucosal vaccination may be an alter-
native approach to current immunization strategies, but effective adjuvants are required. Protein antigens
induce significant mucosal immunoglobulin A (IgA) and systemic IgG responses when administered intrana-
sally (i.n.) with the glyceride-polysorbate based adjuvant RhinoVax (RV) both in experimental animals and
humans. The immunogenicity and efficacy of pneumococcal polysaccharide conjugate vaccines (PNC) of
serotypes 1 and 3 was studied in mice after i.n. immunization with RV. Antibodies were measured in serum
(IgM, IgG, and IgA) and saliva (IgA) and compared to antibody titers induced by parenteral immunization.
The PNCs induced significant systemic IgG and IgA antibodies after i.n. immunization only when given with
RV and, for serotype 1, serum IgG titers were comparable to titers induced by subcutaneous immunization. In
addition, i.n. immunization with PNC-1 in RV elicited detectable mucosal IgA. These results demonstrate that
RV is a potent mucosal adjuvant for polysaccharides conjugated to proteins. A majority of the PNC-1-
immunized mice were protected against both bacteremia and pneumonia after i.n. challenge with a lethal dose
of serotype 1 pneumococci, and protection correlated significantly with the serum IgG titers. Similarly, the
survival of mice immunized i.n. with PNC-3 in RV was significantly prolonged. These results indicate that
mucosal vaccination with PNC and adjuvants may be an alternative strategy for prevention against pneumo-
coccal infections.
The mucosal surfaces of the respiratory, genitourinary, and
gastrointestinal tracts are covered by a specialized epithelium
which creates an efficient physical barrier against environmen-
tal pathogens (19). However, a majority of bacterial and viral
infections directly affect or enter the body through mucosal
surfaces, and colonization at these sites is often the first step in
pathogenesis. Streptococcus pneumoniae is a major pathogen
which enters the body through the respiratory mucosa (34) and
may cause serious infections such as pneumonia, bacteremia,
and meningitis, especially in elderly people with a variety of
chronic diseases and in young children. It is also a common
cause of mucosal infections such as otitis media and sinusitis
(2, 9, 10).
The pneumococcus is surrounded by pneumococcal polysac-
charides (PPS), which are the main virulence factors and pro-
tect the pneumococci from defense mechanisms of the host (1,
37), particularly phagocytosis of bacteria opsonized by type-
specific immunoglobulin G (IgG) antibodies and complement
(24, 35, 37). PPS can induce antibody production in the ab-
sence of T-cell help and are classified as thymus-independent
type 2 (TI-2) antigens. It is thought that the TI-2 antigens only
activate mature B cells, which may be one reason why infants
respond poorly to polysaccharide antigens (23). However, the
responses of children to PPS of different serotypes varies with
age (7, 20). Conjugation of PPS to proteins makes them im-
munogenic in infants (18, 25, 28), and opsonic activity of an-
tibodies has been demonstrated (30, 36). The immunogenicity
of such pneumococcal polysaccharide conjugate vaccines
(PNC) is assumed to be related to their thymus-dependent-like
character (29), although the mechanism is not known in detail.
Systemic vaccination has led to a significant reduction in
morbidity and mortality caused by a variety of pathogens,
where protection has been shown to correlate with serum IgG
antibody titers (26). Nevertheless, systemic immunization does
not induce mucosal immune responses, which may be impor-
tant against infection of the respiratory tract (4, 21). Protection
at mucosal sites may be obtained by stimulation of the muco-
sal-associated lymphoid tissue (MALT), which elicits systemic
IgG response in addition to secretory IgA (S-IgA), the major
antibody isotype at mucosal surfaces (4, 32). S-IgA may inhibit
the adherence and invasion of mucosal pathogens and neutral-
ize the virulence of enzymes and toxins (22, 32, 38). However,
the enormous potential of MALT has not been adequately
exploited in the design of vaccines, partly due to lack of mu-
cosal adjuvants acceptable for human use.
Two potent enterotoxins, cholera toxin and Escherichia coli
heat-labile enterotoxin, are powerful mucosal adjuvants (4,
16). The wild-type forms are toxic, but mutants with reduced
toxicity have been developed (5, 6, 8). RhinoVax (RV) is an
adjuvant formulation based on caprylic-capric glycerides dis-
solved in polysorbate 20 and water, and various protein anti-
gens administered with RV intranasally (i.n.) induce significant
mucosal IgA, as well as systemic IgG responses, both in exper-
imental animals (13, 15) and in humans (12). RV is nontoxic
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and is thus feasible for human use but at high concentrations
(.46%) it may cause increased secretion and a slight initial
stinging, which disappear 5 to 10 min after administration (11).
Susceptibility to different serotypes of S. pneumoniae varies
with the host species, but both types 1 and 3 are virulent in
mice (3, 33). Challenge of NMRI mice i.n. with these serotypes
leads to severe lung infection and bacteremia, although bacte-
remia develops more rapidly with serotype 1 than with sero-
type 3 (33). Both serotypes are important causes of human
diseases (2, 9).
To investigate the potential of mucosal immunization to
protect against pneumococcal infections, mice were immu-
nized i.n. with PNC of serotypes 1 and 3 mixed with RV and
antibody responses measured. At 2 weeks after booster immu-
nization, the mice were challenged with the respective pneu-
mococcal serotype to determine the level of protection against
bacteremia and pulmonary infection.
MATERIALS AND METHODS
Mice. Six-week-old female outbred NMRI mice obtained from Gl. Bomholt-
gård Ltd. (Ry, Denmark) were housed under standard conditions with regulated
daylength and kept in cages with free access to commercial pelleted food and
water.
Vaccines and adjuvants. Experimental tetanus-toxoid conjugated polysaccha-
ride vaccines (i.e., PNC) were produced by Pasteur Merieux Connaught, Marcy
l’Etoile, France. PPS were purchased from American Type Culture Collection
(ATCC, Rockville, Md.). For i.n. immunization, the PNC or PPS were diluted in
saline or mixed with 20% RV, a mucosal adjuvant based on caprylic-capric
glycerides dissolved in polysorbate 20-water and produced at the Department of
Pharmacy, University of Iceland, Reykjavı´k, Iceland (11). For parenteral immu-
nization, PNC-1 was diluted in saline, but PNC-3, which is poorly immunogenic
in mice when administered subcutaneously (s.c.) in saline (unpublished obser-
vation), was emulsified with 50% Freund adjuvant (FA; Sigma Chemical Co., St.
Louis, Mo.), which was complete for primary (FCA) and incomplete for booster
(FIA) treatments.
Immunization. The mice, at 10 animals per group, were immunized with 0.5 or
2.0 mg of PNC or PPS. For i.n. immunization, a 10-ml vaccine solution in RV or
saline was slowly delivered into the nares of mice sedated by s.c. injection with
Hypnorm (Jansen Pharmaceutica, Beerse, Belgium). For parenteral immuniza-
tion, PNC-1 in saline was injected s.c. in the scapular girdle region, and PNC-3
in FA was injected intraperitoneally (i.p.). All groups received a booster with the
same dose and by the same route 4 weeks after the primary immunization.
Nonimmunized mice were used as controls.
Blood and saliva sampling for antibody measurements. The mice were bled
from the retro-orbital sinus 15 days after the boosting; serum was then isolated
and stored at 270°C. Saliva was collected from each mouse by the insertion of
absorbent sticks (Polyfiltronics, Inc., Rockland, Maine) to the mouth. After 5
min, the sticks were transferred to phosphate-buffered saline, pH 7.4 (PBS),
containing 10.0 mg of protease inhibitor (Aprotinin; Sigma) per ml to prevent the
proteolysis of antibodies. The dissolved saliva was pooled for each group of mice
and was stored at 270°C.
Antibodies to PPS. Specific antibodies (IgM, IgG, and IgA) to PPS were
determined by enzyme-linked immunosorbent assay (ELISA) designed accord-
ing to the standardized ELISA protocol (Workshop at the Centers for Disease
Control, Atlanta, Georgia, 1996) with few modifications. Microtiter plates (Maxi-
Sorp; Nunc AS, Roskilde, Denmark) were coated with 10 mg of polysaccharide
of serotypes 1 and 3 (ATCC) per ml of PBS and incubated for 5 h at 37°C. For
neutralization of antibodies to cell wall polysaccharide (CWPS; Statens Serum
Institute, Copenhagen, Denmark), serum samples and standards were diluted
1:50 in PBS with 0.05% Tween 20 (Sigma) and incubated in 500 mg of CWPS per
ml for 30 min at room temperature. The neutralized sera were serially diluted
and incubated in PPS-coated microtiter plates at room temperature for 2 h.
For detection, horseradish peroxidase-conjugated goat antibodies to mouse
IgG (Caltac Laboratories, Burlingame, Calif.), IgM, or IgA (Sera-Lab, Sussex,
United Kingdom) were used. The conjugates were diluted 1:5,000 in PBS-Tween
and incubated for 2 h at room temperature. For development, 3,39,5,59-tetram-
ethylbenzidine peroxidase (Kirkegaard & Perry Laboratories, Gaithersburg,
Md.) was incubated for 10 min according to the manufacturer’s instructions, and
the reaction was stopped by the addition of 0.18 M H2SO4. The absorbance was
measured at 450 nm in an ELISA spectrophotometer (Titertek Multiscan Plus
MK II; Flow Laboratories, Irvine, United Kingdom). Reference serum obtained
from Pasteur Me´rieux Connaught was included on each microtiter plate for the
calculation of the titers expressed in ELISA units (EU) per ml. The titers of the
reference sera (EU/milliliters) corresponded to the inverse of the serum dilution
giving an optical density of 1.0.
The assays were performed at room temperature. All sera were tested in
duplicate, and 100-ml volumes were used in all incubation steps with three
washings with PBS-Tween after each step.
Pneumococci. The bacteria were cultured as described by Saeland et al. (33).
S. pneumoniae of serotypes 1 (ATCC 6301) and 3 (ATCC 6303), maintained in
Tryptoset broth with 20% glycerol at 270°C, were plated on blood agar (Difco
Laboratories, Detroit, Mich.) and incubated at 37°C in 5% CO2 overnight.
Isolated colonies were transferred to a heart infusion broth (Difco) with 10%
horse serum, cultured at 37°C to log phase for 3.5 h, and resuspended in 0.9%
sterile saline. Serial 10-fold dilutions were plated on blood agar to determine the
inoculum density.
Pneumococcal challenge. The challenge experiments (33) were performed 2
days after the mice were bled. The animals were anesthetized with pentobarbi-
tone sodium BP (50 mg/kg; Icelandic Pharmaceuticals, Reykjavı´k, Iceland) in-
jected i.p. and challenged i.n. with 50 ml of bacterial suspension. To evaluate
bacteremia, blood was collected from the tail vein at various time points after
challenge and plated on blood agar for culturing at 37°C in 5% CO2 overnight.
Bacteremia was determined as the number of CFU per milliliter of blood. When
the mice were sacrificed, the lungs were removed and homogenized in sterile
0.9% saline, and serial dilutions were plated on blood agar, including Staph/Strep
selective supplement containing nalidixic acid and colistin sulfate (Unipath Ltd.,
Hamshire, United Kingdom). Pneumococcal lung infection was determined as
the number of CFU per milliliter of lung homogenate. Depending on the first
dilution used, the detection limit was 2.2 CFU/ml of lung homogenate and 1.6
CFU/ml of blood.
Statistical analysis. A nonparametric t test (Mann-Whitney on ranks) was
used to compare antibody titers and CFU numbers between groups. Correlation
was calculated by using Pearson’s coefficients. The chi-square test and Kaplan-
Meier survival test were used to compare survival rates. A P value of ,0.05 was
considered to be statistically significant.
RESULTS
Antibody responses to serotype 1. Mice were immunized i.n.
with either 0.5 or 2.0 mg of PNC-1 or PPS-1, with or without
the mucosal adjuvant RV. Immunization i.n. with either 0.5
and 2.0 mg of PNC-1 in saline elicited very low systemic re-
sponses, but the IgG levels were significantly higher than in
unimmunized control mice (P , 0.001). There was a highly
significant increase in systemic IgG response when PNC-1 was
mixed with RV (P , 0.001; Fig. 1 and Table 1), and immuni-
zation with 2.0 mg of PNC-1 in RV elicited a significantly
higher systemic IgG response than did 0.5 mg of PNC-1 (P 5
0.003). In preliminary studies, we observed that s.c. immuni-
FIG. 1. Type 1-specific serum IgG antibody titers after immunization with
PNC-1 and PPS-1. The box plot shows the median value with the 25th through
the 75th percentiles; the error bars indicate the 5th through the 95th percentiles.
Groups: A, PNC-1 (0.5 mg) in RV given i.n.; B, PNC-1 (2.0 mg) in RV given i.n.;
C, PPS-1 (2.0 mg) in RV given i.n.; D, PNC-1 (0.5 mg) in saline given i.n.; E,
PNC-1 (2.0 mg) in saline given i.n.; F, PPS-1 (2.0 mg) in saline given i.n.; G,
PNC-1 (0.5 mg) in saline given s.c.; H, nonimmunized control.
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zation with 0.5 mg of PNC-1 elicited the highest antibody
response, and thus this dose was used. A 0.5-mg dose of PNC-1
in saline administered s.c. elicited a higher IgG response than
the same dose given i.n. with RV (P 5 0.038), but 2.0 mg of
PNC-1 in RV induced the highest IgG antibody response of all
immunized groups. An i.n. immunization with PPS-1 in RV or
saline elicited very low IgG antibody responses, although the
levels were significantly higher than in unimmunized control
mice (P , 0.001 and P 5 0.004, respectively); they were sig-
nificantly lower than after i.n. immunization with PNC-1 (P ,
0.001). Only those mice immunized with PNC-1 given s.c. (P 5
0.008) and PPS-1 in RV given i.n. (P 5 0.001) showed signif-
icant IgM responses compared to unimmunized control mice
(Table 1). Significant systemic IgA responses (Table 1) were
only elicited in mice immunized i.n. with 2.0 mg of PNC-1 in
RV (P , 0.001), i.n. with PPS-1 in RV (P 5 0.030), and s.c.
with PNC-1 in saline (P 5 0.014). Moreover, a significantly
higher systemic IgA response was observed for the RV group
than for the group immunized s.c. (P , 0.001).
Immunization i.n. with adjuvanted PNC-1 induced mucosal
IgA antibodies, and a 10-fold increase was found for the group
that received 2.0 mg of PNC-1 (3.8 EU/ml) compared to the
control group (,0.2 EU/ml). IgA antibodies were undetect-
able in saliva after i.n. immunization with either dose of PNC-1
in saline (,0.2 EU/ml). Although parenteral immunization
with 0.5 mg of PNC-1 in saline induced a strong serum antibody
response, type 1-specific IgA in saliva was hardly detectable
(0.7 EU/ml).
Antibody responses to serotype 3. Mice were immunized
with 2.0 mg of PNC-3, given i.n. in saline or RV or given i.p. in
FCA or FIA, since PNC-3 is poorly immunogenic when given
s.c. in saline (data not shown). Immunization i.p. with PNC-3
emulsified with FCA or FIA elicited by far the highest type
3-specific IgG antibody titer in serum (Fig. 2). When PNC-3
was administered i.n. with RV, a significant serum IgG anti-
body response was observed (P 5 0.003). Immunization i.n.
with PNC-3 alone or with PPS-3 with or without RV did not
induce significant IgG responses. Neither i.n. nor i.p. immuni-
zation with PNC-3 elicited detectable type 3-specific IgA anti-
body levels in saliva.
Protection against pneumococcal infection caused by sero-
type 1. To evaluate the efficacy of the PNC-1 against bactere-
mia and pulmonary infection, mice were challenged i.n. with
4 3 106 CFU of serotype 1 pneumococci in 50 ml of saline 2
weeks after booster immunization. Serotype 1 is very virulent
in mice, causing heavy lung infection and bacteremia, with
100% deaths occurring between 24 and 30 h after challenge. In
previous experiments, pneumococci were undetectable in lungs
and blood at 24 h in mice vaccinated parenterally with PNC-1.
Thus, we used this time point to evaluate vaccine-induced
protection against invasive pneumococcal infections.
The results of a representative experiment are shown in Fig.
3. Serotype 1 was very virulent and caused severe lung infec-
tion (mean, 7.70 log CFU/ml of lung homogenate [Fig. 3A])
and bacteremia (mean, 5.50 log CFU/ml of blood [Fig. 3B]) in
unimmunized control mice 24 h after i.n. challenge.
FIG. 2. Type 3-specific serum IgG antibody titers after immunization with
PNC-3 and PPS-3. The box plot description is as described for Fig. 1. Groups: A,
PNC-3 in RV given i.n.; B, PPS-3 in RV given i.n.; C, PNC-3 in saline given i.n.;
D, PPS-3 in saline given i.n.; E, PNC-3 in FCA or FIA given i.p.; F, nonimmu-
nized control.
TABLE 1. Type-specific antibodies in sera after immunization with PPS and PNC
Type Vaccine(dose [mg]) Route Adjuvant
Geometric mean titer (EU/ml)a of:
IgG IgM IgA
Type 1
A PNC-1 (0.5) i.n. RV 771 (384–1550) 40 (26–62) 42 (29–62)
B PNC-1 (2.0) i.n. RV 5,365 (2,720–10,583) 55 (33–91) 341 (207–564)
C PPS-1 (2.0) i.n. RV 38 (11–125) 71 (47–106) 52 (37–72)
D PNC-1 (0.5) i.n. Saline 33 (15–74) 11 (5–24) 26 (21–33)
E PNC-1 (2.0) i.n. Saline 220 (132–371) 23 (13–43) 49 (28–85)
F PPS-1 (2.0) i.n. Saline 7 (5–11) 33 (22–48) 45 (28–72)
G PNC-1 (0.5) s.c. Saline 2,562 (882–7,441) 99 (31–312) 62 (40–95)
H Control 3 (3–4) 17 (10–28) 28 (20–42)
Type 3
A PNC-3 (2.0) i.n. RV 48 (12–193) 68 (50–92)
B PPS-3 (2.0) i.n. RV 5 (4–6) 49 (34–70)
C PNC-3 (2.0) i.n. Saline 3 (1–6) 37 (15–78)
D PPS-3 (2.0) i.n. Saline 4 (3–8) 44 (16–121)
E PNC-3 (2.0) i.p. FCA or FIA 1,650 (1,131–2,407) 147 (67–327)
F Control 2 (2–3) 38 (15–97)
a The 95% confidence interval is given in parentheses.
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Immunization with PNC-1 conferred protection against lung
infection caused by serotype 1 (Fig. 3A). Bacteria were cul-
tured from lung homogenate of all unimmunized control mice
24 h after challenge, whereas all mice immunized parenterally
with PNC-1 were completely protected. In addition, 100%
protection in lungs was observed in the group that received 2.0
mg of PNC-1 with RV given i.n. Mice that received 0.5 mg of
PNC-1 mixed with RV had significantly reduced numbers of
pneumococci in the lungs compared to unimmunized control
mice (P , 0.001), and 7 of 10 were fully protected. The three
mice in this group, which had detectable pneumococci (3 to 4
log CFU) in the lungs, all had low serum antibody titers (100
to 1,000 EU/ml). Both groups of mice immunized i.n. with
PNC-1 in saline had reduced pneumococcal density in the
lungs compared to the unimmunized control mice (P , 0.001),
and of those receiving 2.0 mg of PNC-1, 3 of 10 were com-
pletely protected. In contrast, pneumococci were cultured
from the lungs of all mice immunized i.n. with 0.5 mg of PNC-1
in saline. All mice immunized i.n. with PPS-1 in saline were
heavily infected in the lungs, but mice immunized i.n. with
PPS-1 mixed with RV had a reduced pneumococcal density
(P , 0.001), and 4 of 10 mice were protected.
Similarly, immunization with PNC-1 protected against pneu-
mococcal bacteremia (Fig. 3B), and the numbers of CFU in the
blood correlated with the numbers of CFU in the lung homog-
enate (r 5 0.852; P , 0.001). Whereas all control mice had
severe bacteremia, 100% protection was observed for the two
groups that received PNC-1 mixed with RV given i.n.: the
parenterally immunized group and the group immunized i.n.
with 2.0 mg of PNC-1 in saline (Fig. 3B). Of the mice immu-
nized i.n. with 0.5 mg of PNC-1 in saline, 6 of 10 were protected
against bacteremia. Administration i.n. of PPS-1 in RV gave
100% protection from bacteremia, but 5 of 10 mice immunized
i.n. with PPS-1 in saline had detectable pneumococci in the
blood.
The relationship between type 1-specific serum IgG antibod-
ies and pneumococcal density in the lungs and blood is shown
in Fig. 4. Unimmunized mice had hardly detectable levels of
IgG antibodies and were heavily infected. Protection against
lung infection was significantly correlated with type 1-specific
IgG and IgA antibody levels in serum (r 5 20.44 and P ,
0.001 for IgG; r 5 20.350 and P 5 0.002 for IgA), and in all
mice with .1,000 EU/ml of IgG pneumococci were not detect-
able in the lungs (Fig. 4A). However, ;100 EU/ml of IgG in
serum was sufficient to provide protection against bacteremia
(Fig. 4B).
Protection against pneumococcal infection caused by sero-
type 3. We have already demonstrated that serotype 3 is viru-
lent and causes severe lung infection in mice after i.n. chal-
lenge (33). Challenge with .107 CFU of this serotype may also
cause bacteremia, which kills the mice in 1 to 2 days. However,
by reducing the challenge dose, survival may be prolonged.
Figure 5 shows one representative experiment, in which mice
were challenged i.n. with ;104 CFU of type 3 pneumococci in
50 ml of saline and the survival was recorded over a period of
7 days, when the experiment was terminated. At day 7 only
30% of unimmunized control mice had survived, and there was
no difference in survival between the control mice and mice
immunized i.n. with PNC-3 in saline (30%) and with PPS-3 in
saline (40%) or RV (20%). However, 8 of 10 mice immunized
i.n. with PNC-3 in RV (P 5 0.006) and 9 of 10 mice immunized
i.p. with PNC-3 in FCA or FIA (P 5 0.0003) had survived and
looked healthy by day 7. When survival was compared for the
entire duration of the experiment (Kaplan-Meier survival test),
significant protection was observed in groups immunized with
PNC-3 in FCA or FIA given i.p. (P 5 0.0062) and given i.n. in
RV (P 5 0.0164). Nevertheless, when sacrificed at this time
point, low levels of pneumococci (2 to 4 log CFU/ml of lung
homogenate) were detectable in lungs of all mice.
Although there was a highly significant difference in serum
IgG antibody titers between mice immunized i.n. with PNC-3
in RV and those immunized i.p. in FA (P , 0.001), there was
no difference in survival between the immunization routes
(P 5 0.290), indicating that serum IgG antibodies elicited by
i.n. immunization (Fig. 2 and Table 1) were sufficient to protect
the mice from severe pneumococcal lung infection by type 3.
DISCUSSION
Since the mucosal epithelium of the nasopharynx is the pri-
mary site of pneumococcal colonization (34, 37), i.n. vaccina-
tion may offer an alternative approach to current strategies
since it induces mucosal as well as systemic immune responses.
In addition, such vaccination is painless and easy to perform,
FIG. 3. Pneumococcal density (mean log 6 the standard deviation) in the
lungs (A) and blood (B) in groups of mice at 24 h after i.n. challenge with
serotype 1. Each group is represented by one dot (n 5 10). Groups: A, PNC-1
(0.5 mg) in RV given i.n.; B, PNC-1 (2.0 mg) in RV given i.n.; C, PPS-1 (2.0 mg)
in RV given i.n.; D, PNC-1 (0.5 mg) in saline given i.n.; E, PNC-1 (2.0 mg) in
saline given i.n.; F, PPS-1 (2.0 mg) in saline given i.n.; G, PNC-1 (0.5 mg) in saline
given s.c.; H, nonimmunized control.
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which may favor these strategies for the vaccination of infants
and children.
Immunization i.n. has been investigated by the administra-
tion of antigens together with adjuvants, such as cholera toxin
B (CTB) (4) and mutants of Escherichia coli heat-labile en-
terotoxin with reduced toxicity (5). These enterotoxins change
the permeability of the mucosa and enhance the transepithelial
flux of antigens from the lumen to the lamina propria (14). In
this study we used the mucosal adjuvant RV, which is based on
caprylic-capric glycerides dissolved in polysorbate 20 and wa-
ter. RV enhances mucosal as well as systemic antibody re-
sponses to various bacterial and viral protein antigens, both in
experimental animals (13, 15) and in humans (12). The bio-
logical mechanisms of this adjuvant are still under investiga-
tion.
The immunogenicity of two PNC (PNC-1 and PNC-3) was
studied when administered i.n. with RV, and the extent of
protection against infection with the corresponding pneumo-
coccal serotypes was evaluated. For PNC-1, i.n. immunization
with RV was as efficient as immunization by the s.c. route, both
in terms of immunogenicity and protection against pneumo-
coccal pneumonia and bacteremia. Even though i.n. immuni-
zation with the corresponding polysaccharide PPS-1 in RV
elicited a significant systemic IgG response, this was not suffi-
cient to protect against pulmonary infection. Thus, among the
doses tested, PPS was less effective than PNC for mucosal
immunization against pneumococcal infections.
We have previously shown a prolonged survival of up to 11
days in mice immunized i.p. with PNC-3 in FCA or FIA and
that most of the deaths occur between days 2 and 4 in unim-
munized mice, with very few deaths occurring after day 5
(unpublished data). We now compared the survival of mice
immunized i.n. with PNC-3 in RV and PNC-3 in FCA or FIA
given i.p. Although use of the i.n. route induced a significantly
lower systemic IgG response compared to use of the i.p. route,
the i.n. immunization reduced the severity of infection caused
by type 3 pneumococci and prolonged survival to a similar
degree.
Mucosal IgA antibody response to PNC-1 in RV but not to
PNC-3 was observed. Thus, salivary IgA does not seem to be
necessary for protection against infection following i.n. chal-
lenge with a large inoculum in this mouse model. Although
measurements of IgA to various protein antigens were found
to be comparable in saliva and mucosal tissues (10a), low levels
of mucosal IgA antibodies may not be detected in saliva. Im-
munization of mice i.n. with pneumococcal surface protein A
with CTB as a adjuvant has been shown to induce salivary IgA
antibodies and to provide protection against carriage of S.
pneumoniae, indicating a role of IgA antibodies in protection
of mucosal surfaces. Immunization with 6B conjugate and CTB
induced marginal salivary IgA response but detectable serum
IgG and reduced nasopharyngeal colonization (38).
Systemic IgG antibodies to PPS are known to correlate with
protection against pneumococcal infections, and passive im-
munization with IgG preparations containing high levels of
antibodies to bacterial polysaccharides protects infants and
young children at high risk (27, 31). We have demonstrated the
immunogenicity of the octavalent PNC in infants, and the
infant sera had both opsonic activity in vitro (17) and were
protective against serotypes 6A and 6B by passive immuniza-
FIG. 4. Relationship between pneumococcal lung infection (A) and bactere-
mia (B) (as log CFU) and type 1-specific IgG antibody titers in serum. Each
symbol represents one mouse. Groups: PNC-1 (0.5 mg) in RV given i.n. (),
PNC-1 (2.0 mg) in RV given i.n. (), PPS-1 in RV given i.n. ({), PNC-1 (0.5 mg)
in saline given i.n. (F), PNC-1 (2.0 mg) in saline given i.n. (E), PPS-1 in saline
given i.n. (}), PNC-1 (0.5 mg) in saline given s.c. ( k ), nonimmunized control (h).
The dotted lines represent the detection limits for CFU.
FIG. 5. Survival of mice (n 5 10 per group) after i.n. challenge with pneu-
mococci of serotype 3.
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tion in this mouse model (unpublished data). It has also been
postulated that inflammatory responses to infections at muco-
sal surfaces induce transudation of serum IgG and phagocytes,
which may clear the infections at the mucosal surfaces (26).
RV is well tolerated, and its adjuvant activity has been dem-
onstrated in humans (12). In this study we demonstrated that
i.n. immunization with PNC-1 and PNC-3 in RV protected
mice against infection after i.n. challenge with the respective
pneumococcal serotypes and that the protection was related to
the levels of type-specific serum IgG antibodies. These results
indicate that mucosal vaccination with PNC may offer an al-
ternative approach to current strategies for preventing pneu-
mococcal diseases.
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